• Home
  • Search Results
  • Use of a novel chagas urine nanoparticle test (chunap) for diagnosis of congenital chagas disease.

Use of a novel chagas urine nanoparticle test (chunap) for diagnosis of congenital chagas disease.

PLoS neglected tropical diseases (2014-10-03)
Yagahira E Castro-Sesquen, Robert H Gilman, Gerson Galdos-Cardenas, Lisbeth Ferrufino, Gerardo Sánchez, Edward Valencia Ayala, Lance Liotta, Caryn Bern, Alessandra Luchini

Detection of congenital T. cruzi transmission is considered one of the pillars of control programs of Chagas disease. Congenital transmission accounts for 25% of new infections with an estimated 15,000 infected infants per year. Current programs to detect congenital Chagas disease in Latin America utilize microscopy early in life and serology after 6 months. These programs suffer from low sensitivity by microscopy and high loss to follow-up later in infancy. We developed a Chagas urine nanoparticle test (Chunap) to concentrate, preserve and detect T. cruzi antigens in urine for early, non-invasive diagnosis of congenital Chagas disease. This is a proof-of-concept study of Chunap for the early diagnosis of congenital Chagas disease. Poly N-isopropylacrylamide nano-particles functionalized with trypan blue were synthesized by precipitation polymerization and characterized with photon correlation spectroscopy. We evaluated the ability of the nanoparticles to capture, concentrate and preserve T. cruzi antigens. Urine samples from congenitally infected and uninfected infants were then concentrated using these nanoparticles. The antigens were eluted and detected by Western Blot using a monoclonal antibody against T. cruzi lipophosphoglycan. The nanoparticles concentrate T. cruzi antigens by 100 fold (western blot detection limit decreased from 50 ng/ml to 0.5 ng/ml). The sensitivity of Chunap in a single specimen at one month of age was 91.3% (21/23, 95% CI: 71.92%-98.68%), comparable to PCR in two specimens at 0 and 1 month (91.3%) and significantly higher than microscopy in two specimens (34.8%, 95% CI: 16.42%-57.26%). Chunap specificity was 96.5% (71/74 endemic, 12/12 non-endemic specimens). Particle-sequestered T. cruzi antigens were protected from trypsin digestion. Chunap has the potential to be developed into a simple and sensitive test for the early diagnosis of congenital Chagas disease.

Product Number
Product Description

N-Hydroxysuccinimide, 98%
Acrylic acid, anhydrous, contains 200 ppm MEHQ as inhibitor, 99%
Potassium persulfate, ACS reagent, ≥99.0%
Potassium peroxodisulfate, puriss. p.a., ACS reagent, ≥99.0% (RT)
Trehalose, Pharmaceutical Secondary Standard; Certified Reference Material
Potassium persulfate, 99.99% trace metals basis
N-Hydroxysuccinimide, purum, ≥97.0% (T)
Trehalose, United States Pharmacopeia (USP) Reference Standard

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.